Epidemiologic features and therapeutic strategies of kerion: A nationwide multicentre study.
Humans
Child, Preschool
Antifungal Agents
/ therapeutic use
Male
Female
Tinea Capitis
/ drug therapy
Itraconazole
/ therapeutic use
China
/ epidemiology
Microsporum
/ isolation & purification
Child
Infant
Glucocorticoids
/ therapeutic use
Treatment Outcome
Dermatitis, Atopic
/ drug therapy
Risk Factors
Adolescent
Adult
Middle Aged
Retrospective Studies
antifungal agents
cutaneous infection
dermatophytes
dermatophytosis
epidemiology
tinea capitis
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
revised:
13
04
2024
received:
20
02
2024
accepted:
26
05
2024
medline:
3
6
2024
pubmed:
3
6
2024
entrez:
2
6
2024
Statut:
ppublish
Résumé
Kerion is a severe type of tinea capitis that is difficult to treat and remains a public health problem. To evaluate the epidemiologic features and efficacy of different treatment schemes from real-world experience. From 2019 to 2021, 316 patients diagnosed with kerion at 32 tertiary Chinese hospitals were enrolled. We analysed the data of each patient, including clinical characteristics, causative pathogens, treatments and outcomes. Preschool children were predominantly affected and were more likely to have zoophilic infection. The most common pathogen in China was Microsporum canis. Atopic dermatitis (AD), animal contact, endothrix infection and geophilic pathogens were linked with kerion occurrence. In terms of treatment, itraconazole was the most applied antifungal agent and reduced the time to mycological cure. A total of 22.5% of patients received systemic glucocorticoids simultaneously, which reduced the time to complete symptom relief. Furthermore, glucocorticoids combined with itraconazole had better treatment efficacy, with a higher rate and shorter time to achieving mycological cure. Kerion often affects preschoolers and leads to serious sequelae, with AD, animal contact, and endothrix infection as potential risk factors. Glucocorticoids, especially those combined with itraconazole, had better treatment efficacy.
Sections du résumé
BACKGROUND
BACKGROUND
Kerion is a severe type of tinea capitis that is difficult to treat and remains a public health problem.
OBJECTIVES
OBJECTIVE
To evaluate the epidemiologic features and efficacy of different treatment schemes from real-world experience.
METHODS
METHODS
From 2019 to 2021, 316 patients diagnosed with kerion at 32 tertiary Chinese hospitals were enrolled. We analysed the data of each patient, including clinical characteristics, causative pathogens, treatments and outcomes.
RESULTS
RESULTS
Preschool children were predominantly affected and were more likely to have zoophilic infection. The most common pathogen in China was Microsporum canis. Atopic dermatitis (AD), animal contact, endothrix infection and geophilic pathogens were linked with kerion occurrence. In terms of treatment, itraconazole was the most applied antifungal agent and reduced the time to mycological cure. A total of 22.5% of patients received systemic glucocorticoids simultaneously, which reduced the time to complete symptom relief. Furthermore, glucocorticoids combined with itraconazole had better treatment efficacy, with a higher rate and shorter time to achieving mycological cure.
CONCLUSIONS
CONCLUSIONS
Kerion often affects preschoolers and leads to serious sequelae, with AD, animal contact, and endothrix infection as potential risk factors. Glucocorticoids, especially those combined with itraconazole, had better treatment efficacy.
Substances chimiques
Antifungal Agents
0
Itraconazole
304NUG5GF4
Glucocorticoids
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13751Subventions
Organisme : National High Level Hospital Clinical Research Funding (High Quality Clinical Research Project of Peking University First Hospital)
Organisme : National Key Research and Development Program of China
Informations de copyright
© 2024 Wiley‐VCH GmbH. Published by John Wiley & Sons Ltd.
Références
Leung AKC, Hon KL, Leong KF, Barankin B, Lam JM. Tinea capitis: An updated review. Recent Patents Inflamm Allergy Drug Discov. 2020;14(1):58‐68. doi:10.2174/1872213x14666200106145624
John AM, Schwartz RA, Janniger CK. The kerion: An angry tinea capitis. Int J Dermatol. 2018;57(1):3‐9. doi:10.1111/ijd.13423
Rajkumar A, Britton PN. Kerion: a great mimicker. Med J Aust. 2022;216(11):563‐567. doi:10.5694/mja2.51588
Shemer A, Lyakhovitsky A, Kaplan B, et al. Diagnostic approach to tinea capitis with kerion: a retrospective study. Pediatr Dermatol. 2022;39(5):708‐712. doi:10.1111/pde.15021
Le TK, Cohen BA. Tinea capitis: advances and a needed paradigm shift. Curr Opin Pediatr. 2021;33(4):387‐391. doi:10.1097/mop.0000000000001034
Aneke CI, Otranto D, Cafarchia C. Therapy and antifungal susceptibility profile of microsporum canis. Journal of Fungi (Basel, Switzerland). 2018;4(3):107. doi:10.3390/jof4030107
Mao L, Zhang L, Li H, et al. Pathogenic fungus Microsporum canis activates the NLRP3 inflammasome. Infect Immun. 2014;82(2):882‐892. doi:10.1128/iai.01097-13
Gianni C, Betti R, Perotta E, Crosti C. Tinea capitis in adults. Mycoses. 1995;38(7–8):329‐331. doi:10.1111/j.1439-0507.1995.tb00417.x
Mayser P, Nenoff P, Reinel D, et al. S1 guidelines: Tinea capitis. Journal of the German Society of Dermatol. 2020;18(2):161‐179. doi:10.1111/ddg.14026
Chinese Association Hematologists; Chinese Invasive Fungal Infection Working Group. Chinese guidelines for the diagnosis and treatment of tinea capitis (2018 revision). Chin J Mycol. 2019;14(1):4‐6.
Garcia Garces H, Hrycyk MF, Giacobino J, et al. Molecular identification and phylogenetical analysis of dermatophyte fungi from Latin America. Mycoses. 2016;59(12):787‐797. doi:10.1111/myc.12532
Rezaei‐Matehkolaei A, Mirhendi H, Makimura K, et al. Nucleotide sequence analysis of beta tubulin gene in a wide range of dermatophytes. Med Mycol. 2014;52(7):674‐688. doi:10.1093/mmy/myu033
Chowdhary A, Singh A, Singh PK, Khurana A, Meis JF. Perspectives on misidentification of trichophyton interdigitale/trichophyton mentagrophytes using internal transcribed spacer region sequencing: urgent need to update the sequence database. Mycoses. 2019;62(1):11‐15. doi:10.1111/myc.12865
Kandemir H, Dukik K, Hagen F, Ilkit M, Gräser Y, de Hoog GS. Polyphasic discrimination of trichophyton tonsurans and t. Equinum from Humans and Horses Mycopathologia. 2020;185(1):113‐122. doi:10.1007/s11046-019-00344-9
Xiao YY, Zhou YB, Chao JJ, Ma L. Epidemiology of tinea capitis in children in Beijing and adjacent regions, China: a 15‐year retrospective study. Mycopathologia. 2023;188(5):531‐535. doi:10.1007/s11046-022-00649-2
Zhan P, Li D, Wang C, et al. Epidemiological changes in tinea capitis over the sixty years of economic growth in China. Med Mycol. 2015;53(7):691‐698. doi:10.1093/mmy/myv057
Chen XQ, Zheng DY, Xiao YY, et al. Aetiology of tinea capitis in China: a multicentre prospective study. Br J Dermatol. 2022;186(4):705‐712. doi:10.1111/bjd.20875
Bongomin F, Olum R, Nsenga L, et al. Estimation of the burden of tinea capitis among children in Africa. Mycoses. 2021;64(4):349‐363. doi:10.1111/myc.13221
Chen XQ, Yu J. Global demographic characteristics and pathogen spectrum of tinea capitis. Mycopathologia. 2023;188(5):433‐447. doi:10.1007/s11046-023-00710-8
Zhi H, Shen H, Zhong Y, et al. Tinea capitis in children: a single‐institution retrospective review from 2011 to 2019. Mycoses. 2021;64(5):550‐554. doi:10.1111/myc.13243
Takwale A, Agarwal S, Holmes SC, Berth‐Jones J. Tinea capitis in two elderly women: transmission at the hairdresser. Br J Dermatol. 2001;144(4):898‐900. doi:10.1046/j.1365-2133.2001.04154.x
Martin ES, Elewski BE. Tinea capitis in adult women masquerading as bacterial pyoderma. J Am Acad Dermatol. 2003;49(2):177‐179. doi:10.1067/mjd.2003.327
Rodríguez‐Cerdeira C, Martínez‐Herrera E, Szepietowski JC, et al. A systematic review of worldwide data on tinea capitis: analysis of the last 20 years. Journal of the European Academy of Dermatology and Venereology: JEADV. 2021;35(4):844‐883. doi:10.1111/jdv.16951
Liang G, Zheng X, Song G, et al. Adult tinea capitis in China: a retrospective analysis from 2000 to 2019. Mycoses. 2020;63(8):876‐888. doi:10.1111/myc.13102
Wang HN, Shang CS, Yang SJ, et al. Clinical and epidemiological characteristics of tinea capitis in northern Taiwan during 2014‐2019: An unusual bimodal distribution of patients and comparison of paediatric and adult cases. Mycoses. 2021;64(5):484‐494. doi:10.1111/myc.13234
Getso MI, Hashemi SJ, Ghazvini RD, et al. Determination of dermatophytes isolated from tinea capitis using conventional and ITS‐based sequencing methods in Kano, Nigeria. J Mycol Médicale. 2021;31(3):101157. doi:10.1016/j.mycmed.2021.101157
Zaraa I, Hawilo A, Aounallah A, et al. Inflammatory tinea capitis: a 12‐year study and a review of the literature. Mycoses. 2013;56(2):110‐116. doi:10.1111/j.1439-0507.2012.02219.x
Ely JW, Rosenfeld S, Stone MS. Diagnosis and management of tinea infections. Am Fam Physician. 2014;90(10):702‐710.
Ross IL, Weldhagen GF, Kidd SE. Detection and identification of dermatophyte fungi in clinical samples using a commercial multiplex tandem PCR assay. Pathology. 2020;52(4):473‐477. doi:10.1016/j.pathol.2020.03.002
Arenas R, Toussaint S, Isa‐Isa R. Kerion and dermatophytic granuloma. Mycological and histopathological findings in 19 children with inflammatory tinea capitis of the scalp. Int J Dermatol. 2006;45(3):215‐219. doi:10.1111/j.1365-4632.2004.02449.x
Ma Y, Deng W, Zhang K, et al. Dual RNA‐sequencing and liquid chromatography–mass spectrometry unveil specific insights on the pathogenicity of trichophyton mentagrophytes complex. J Invest Dermatol. 2013;143(3):470‐479.e6. doi:10.1016/j.jid.2022.08.055
Isa‐Isa R, Arenas R, Isa M. Inflammatory tinea capitis: kerion, dermatophytic granuloma, and mycetoma. Clin Dermatol. 2010;28(2):133‐136. doi:10.1016/j.clindermatol.2009.12.013
Nenoff P, Krüger C, Ginter‐Hanselmayer G, Tietz HJ. Mycology—an update. Part 1: dermatomycoses: causative agents, epidemiology and pathogenesis. J German Society Dermatol. 2014;12(3):188‐209;quiz 212. doi:10.1111/ddg.12245
Wei LW, Qiao JJ. Mini‐review: the diagnostic methods of tinea capitis. Mycopathologia. 2023;188(5):563‐569. doi:10.1007/s11046-023-00731-3
Zhou X, Liu W, Yang S, et al. Exploring the clinical features and risk factors for children tinea capitis complicated with allergic diseases. Mycoses. 2023;66(4):338‐345. doi:10.1111/myc.13558
Woodfolk JA. Allergy and dermatophytes. Clin Microbiol Rev. 2005;18(1):30‐43. doi:10.1128/cmr.18.1.30-43.2005
Cruciani D, Papini M, Broccatelli S, et al. Presumptive zoonotic kerion by Nannizzia gypsea: case report. Front Vet Sci. 2021;8:718766. doi:10.3389/fvets.2021.718766
Ginter G. Ecology, epidemiology and clinical symptomatology of microsporum gypseum infections. Mycoses. 1989;32(10):531‐535.
Romano C, Valenti L, Barbara R. Dermatophytes isolated from asymptomatic stray cats. Mycoses. 1997;40(11–12):471‐472. doi:10.1111/j.1439-0507.1997.tb00187.x
Peixoto R, Meneses OMS, da Silva FO, Donati A, Veasey JV. Tinea capitis: correlation of clinical aspects, findings on direct mycological examination, and agents isolated from fungal culture. Int J Trichol. 2019;11(6):232‐235. doi:10.4103/ijt.ijt_88_19
Genedy RM, Sorour OA, Elokazy MAW. Trichoscopic signs of tinea capitis: a guide for selection of appropriate antifungal. Int J Dermatol. 2021;60(4):471‐481. doi:10.1111/ijd.15289
Goto Y, Suzuki T, Suzuki Y, et al. Trichophyton tonsurans‐induced kerion celsi with decreased defensin expression and paradoxically increased interleukin‐17A production. J Dermatol. 2019;46(9):794‐797. doi:10.1111/1346-8138.15008
Shimoyama H, Yo A, Makimura K, Sei Y, Kuwano Y. A case of tinea faciei due to nannizzia gypsea: inflammatory eruption on the medial angle of the eyelid. Mycopathologia. 2020;185(4):699‐703. doi:10.1007/s11046-020-00474-5
Illner A, Michl C, Sunderkötter C, et al. Paraphyton mirabile‐a rare geophilic dermatophyte‐with unclear relation to nail disease. J Euro Acad Dermatol Venereol. Online ahead of print. doi:10.1111/jdv.19066
Uhrlaß S, Mayser P, Schwarz R, et al. Dermatomycoses due to nannizzia praecox (formerly microsporum praecox) in Germany: case reports and review of the literature. Mycopathologia. 2018;183(2):391‐398. doi:10.1007/s11046-017-0213-x
García‐Martos P, Ruiz‐Aragón J, García‐Agudo L, Linares M. Dermatophytoses due to Microsporum gypseum: report of eight cases and literature review. Rev Iberoam Micol. 2004;21(3):147‐149.
Romano C, Massai L, Gallo A, Fimiani M. Microsporum gypseum infection in the Siena area in 2005‐2006. Mycoses. 2009;52(1):67‐71. doi:10.1111/j.1439-0507.2008.01543.x
de Arroyave BS, Yepes A, Arenas J, de Uribe LS, Restrepo A. Epidemic outbreak of tinea corporis due to Microsporum gypseum. Mycopathologia. 1977;60(3):135‐138. doi:10.1007/bf00448404
Friedland R, Sabbah F, Reiss‐Huss S, Amitai DB. Epidemiologic features and risk of scarring in pediatric patients with kerion celsi. Pediatr Dermatol. 2022;39(2):215‐219. doi:10.1111/pde.14916
Chen S, Sun KY, Feng XW, Ran X, Lama J, Ran YP. Efficacy and safety of itraconazole use in infants. World J Pediatr. 2016;12(4):399‐407. doi:10.1007/s12519-016-0034-x
Chen X, Jiang X, Yang M, et al. Systemic antifungal therapy for tinea capitis in children. Cochrane Database Syst Rev. 2016;2016(5):Cd004685. doi:10.1002/14651858.CD004685.pub3
Chinese Diagnosis and Treatment Guidelines of Tinea Capitis Working group. Guidelines for diagnosis and treatment of tinea capitis in China(2018). Chinese J Mycol. 2019;14(1):4‐6.
Xiong XX, Zhang Z, Yang J, Sui W. Curative effect of itraconazole combined with prednisone in the treatment of children with kerion. J North Sichuan Med Coll. 2008;23(2):146‐148. doi:10.3969/j.issn.1005-3697.2008.02.014
Vandewalle J, Luypaert A, de Bosscher K, Libert C. Therapeutic mechanisms of glucocorticoids. Trends Endocrinol Metab. 2018;29(1):42‐54. doi:10.1016/j.tem.2017.10.010
Aneke CI, Rhimi W, Hubka V, Otranto D, Cafarchia C. Virulence and antifungal susceptibility of Microsporum canis strains from animals and humans. Antibiotics (Basel). 2021;10(3):296. doi:10.3390/antibiotics10030296
Wilkinson L, Verhoog NJD, Louw A. Disease‐ and treatment‐associated acquired glucocorticoid resistance. Endocr Connect. 2018;7(12):R328‐R349. doi:10.1530/ec-18-0421